Shenzhen Salubris Pharmaceuticals Co., Ltd. to Speak at ACCESS CHINA BD Forum @ BIO

June 15, 2025 (Boston) — We are glad to announce that Jane Wang, the CSO of Shenzhen Salubris Pharmaceuticals Co., Ltd., will be presenting at the ACCESS CHINA BD Forum @BIO on June 15, 2025. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

Shenzhen Salubris Pharmaceuticals Co., Ltd. (Stock Code: 002294), founded in 1998 and listed on the Shenzhen Stock Exchange in 2009, is an innovation-driven pharmaceutical company headquartered in Shenzhen, China, with a global outlook. The company integrates R&D, production, and sales, focusing on addressing unmet medical needs in chronic diseases such as cardiovascular and cerebrovascular diseases, diabetes, cancer, autoimmune/inflammatory osteoporosis, and chronic kidney disease.

Salubris possesses full-spectrum capabilities in innovative drug discovery and development, supported by five global R&D centers. Its innovation platforms focus on small-molecule and peptide drugs, biological drugs, siRNA-based therapeutics, gene-editing therapies, and medical devices, aiming to deliver clinically meaningful innovative products.

About the speaker

Dr. Jane Wang boasts over 26 years of extensive experience in drug research and development, having worked at Pfizer in the U.S. and WuXi AppTec. She currently holds the position of Chief Scientific Officer at Shenzhen Salubris Pharmaceuticals, where she leads and develops innovation platforms encompassing small molecules, cyclic peptides, siRNA, and AOC, with the goal of delivering clinically significant innovative products.

Salubris Pharmaceuticals is an innovation-driven pharmaceutical company with a global perspective. It integrates research and development, production, and sales, focusing on addressing unmet medical needs in chronic diseases such as cardiovascular and cerebrovascular diseases, diabetes, cancer, osteoporosis, and chronic kidney disease.

About ACCESS CHINA BD Forum @BIO

‘ACCESS CHINA BD Forum @BIO is scheduled to be held on June 15, 2025, at Seaport Boston Hotel. This year’s ACCESS CHINA BD Forum @BIO will convene 80 distinguished guests for an afternoon of strategic networking, business development, and thought leadership, with a special emphasis on China’s dynamic biotechnology landscape and global collaboration opportunities.

Conference Name: ACCESS CHINA BD Forum @BIO

Date: June 15, 2025

Content: Keynote Speeches, Panel Discussion, 10 Elevator Pitch, and Closed-Door Dinner Reception.

Participants: Pharma/Biotech senior management and BD’s

View more information at https://biotochina.org/